Josep Maria Ribera Santasusana

Chief of the Department

Institut Català d'Oncologia

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Josep Maria Ribera Santasusana is the Chief of the Department at the Institut Català d'Oncologia Badalona, Spain. His research focuses on acute lymphoblastic leukemia, particularly in treatment strategies and outcomes for Philadelphia chromosome-positive patients. He has contributed to several notable articles discussing therapeutic advances, prognostic factors, and patient-reported outcomes in the field.

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (6)

ISABEL CANO FERRI

Instituto de Investigación Sanitaria La Fe

SPAIN

View details

Jesús María Hernández-Rivas

Universidad de Salamanca

SPAIN

View details

M ROCIO BENITO SANCHEZ

Professor

Universidad de Salamanca

SPAIN

View details

Elias J. Jabbour

UNITED STATES

View details

Amir Enshaei

Newcastle University

UNITED KINGDOM

View details

Gustavo Tapia Melendo

University of Barcelona

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Josep Maria Ribera Santasusana

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

Treatment of Philadelphia positive acute lymphoblastic leukemia

Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial

The evolving therapeutic revolution in adult acute lymphoblastic leukemia

Quality‐Adjusted Time Without Symptoms of Disease or Toxicity (Q‐TWiST) in Patients With Newly Diagnosed Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib

A DNA methylation database of human and mouse hematological malignancy cell lines

Novel prognostic factors and therapeutic advances in adult acute lymphoblastic leukemia

Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions

Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia

MRD: also for T-lymphoblastic lymphoma

Ponalfil trial for adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia: Long‐term results

A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study

Preferential Genetic Pathways Lead to Relapses in Adult B-Cell Acute Lymphoblastic Leukemia

Diffuse Large B-Cell Lymphoma in the HIV Setting

Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison

HHV8 and EBV‐negative primary effusion‐based lymphoma: A case report of a new provisional entity and review of literature

T-ALL in CNS-3 status needs improvement

JZP458 closes the asparaginase allergy gap

Collaborators (6)

ISABEL CANO FERRI

Jesús María Hernández-Rivas

M ROCIO BENITO SANCHEZ

Elias J. Jabbour

Amir Enshaei

Gustavo Tapia Melendo

Make your next move.